These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35087141)

  • 1. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
    Nakai M; Yamamoto Y; Baba M; Suda G; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Sho T; Morikawa K; Ogawa K; Furuya K; Sakamoto N
    Sci Rep; 2022 Jan; 12(1):1449. PubMed ID: 35087141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
    Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
    Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB
    PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis.
    John BV; Dang Y; Kaplan DE; Jou JH; Taddei TH; Spector SA; Martin P; Bastaich DR; Chao HH; Dahman B
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):778-788.e7. PubMed ID: 38061410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
    Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
    Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients.
    Wang HM; Hung CH; Lu SN; Chen CH; Lee CM; Hu TH; Wang JH
    Liver Int; 2013 May; 33(5):756-61. PubMed ID: 23405889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
    Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
    J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study.
    Morisco F; Federico A; Marignani M; Lombardo FL; Cossiga V; Ranieri L; Romeo M; Cipullo M; Begini P; Zannella A; Stroffolini T
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.
    Narita Y; Genda T; Tsuzura H; Sato S; Kanemitsu Y; Ishikawa S; Kikuchi T; Hirano K; Iijima K; Wada R; Ichida T
    J Gastroenterol Hepatol; 2014 Jan; 29(1):137-43. PubMed ID: 24117602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
    Semmler G; Alonso López S; Pons M; Lens S; Dajti E; Griemsmann M; Zanetto A; Burghart L; Hametner-Schreil S; Hartl L; Manzano M; Rodriguez-Tajes S; Zanaga P; Schwarz M; Gutierrez ML; Jachs M; Pocurull A; Polo B; Ecker D; Mateos B; Izquierdo S; Real Y; Ahumada A; Bauer DJM; Mauz JB; Casanova-Cabral M; Gschwantler M; Russo FP; Azzaroli F; Maasoumy B; Reiberger T; Forns X; Genesca J; Bañares R; Mandorfer M;
    J Hepatol; 2024 Jul; 81(1):76-83. PubMed ID: 38521170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness.
    Dajti E; Marasco G; Ravaioli F; Colecchia L; Ferrarese A; Festi D; Colecchia A
    JHEP Rep; 2021 Jun; 3(3):100289. PubMed ID: 34095798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
    You MW; Kim KW; Shim JJ; Pyo J
    J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?
    Ragazzo TG; Zitelli PMY; Mazo DF; Oliveira CP; Carrilho FJ; Pessoa MG
    Clinics (Sao Paulo); 2024; 79():100381. PubMed ID: 38733689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
    Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus.
    Kumada T; Toyoda H; Yasuda S; Sone Y; Ogawa S; Takeshima K; Tada T; Ito T; Sumida Y; Tanaka J
    Clin Transl Gastroenterol; 2021 Apr; 12(4):e00337. PubMed ID: 33888672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
    Tong MJ; Theodoro CF; Salvo RT
    J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.